1α,25-Dihydroxyvitamin D3 up-regulates IL-34 expression in SH-SY5Y neural cells

Innate Immun. 2017 Oct;23(7):584-591. doi: 10.1177/1753425917725391. Epub 2017 Aug 17.

Abstract

Vitamin D supplementation is regarded as a novel approach to treat Alzheimer's disease, but the underlying mechanism remains elusive. The cytokine IL-34 provides strong neuroprotective and survival signals in brain injury and neurodegeneration and could be an immunological mediator for the vitamin D-induced protection. The aim of this study was to investigate whether human IL-34 is up-regulated in neuronal cells by the hormonally active form of vitamin D, 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3]. We found that IL-34 was detectable in a variety of cell lines and its expression was strongly induced in SH-SY5Y neural cells in a dose- and time-dependent manner by 1α,25(OH)2D3 through the vitamin D receptor (VDR). Furthermore, we identified the core promoter of IL-34 gene and a VDR binding site (CGCCCT) that was required for 1α,25(OH)2D3-induced IL-34 expression. These findings suggest that the induction of IL-34 expression by 1α,25(OH)2D3 may constitute a mechanism that explains the protective function of vitamin D in Alzheimer's disease.

Keywords: 1α; 25-Dihydroxyvitamin D3; Alzheimer disease; IL-34; expression; neuronal cell.

MeSH terms

  • Alzheimer Disease / diet therapy*
  • Cell Line
  • Cholecalciferol / pharmacology*
  • Cholecalciferol / therapeutic use
  • Humans
  • Interleukins / genetics
  • Interleukins / metabolism*
  • Neurons / drug effects*
  • Neurons / physiology
  • Neuroprotective Agents / pharmacology*
  • Neuroprotective Agents / therapeutic use
  • Promoter Regions, Genetic / genetics
  • Receptors, Calcitriol / metabolism
  • Up-Regulation

Substances

  • IL34 protein, human
  • Interleukins
  • Neuroprotective Agents
  • Receptors, Calcitriol
  • Cholecalciferol